DHRS4-AS1 Gene: Potential Drug Target Or Biomarker for Various Diseases

Target Name: DHRS4-AS1

NCBI ID: G55449

DHRS4-AS1

DHRS4-AS1 Gene: Potential Drug Target Or Biomarker for Various Diseases

DHRS4-AS1 (C14orf67), a gene located on chromosome 14, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function and potential in these areas has been the focus of extensive research in recent years, and its potential as a drug target continues to generate interest among scientists and healthcare professionals.

The DHRS4-AS1 gene, also known as C14orf67, is a non-coding RNA gene that has been identified in various organisms, including humans. It is located on chromosome 14, which is the second-longest chromosome in the human body and is responsible for various physiological functions, including growth, development, and reproduction.

One of the key features of the DHRS4-AS1 gene is its potential as a drug target. The gene has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function in these areas has been the focus of extensive research, and its potential as a drug target continues to generate interest among scientists and healthcare professionals.

For example, studies have shown that DHRS4-AS1 is involved in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. In addition, the gene has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, DHRS4-AS1 has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, the gene has also been shown to play a role in the development and progression of various diseases, including aging and age-related diseases.

The potential of DHRS4-AS1 as a drug target is based on its involvement in various physiological processes and its ability to interact with various signaling pathways. For example, studies have shown that DHRS4-AS1 is involved in the regulation of cell growth, cell cycle progression, and apoptosis. It is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed, and has been shown to play a role in the development of various diseases, including cancer.

In addition, DHRS4-AS1 has also been shown to be involved in the regulation of inflammation and immune responses. Its expression has been shown to be associated with various immune cell types, including T cells and natural killer cells, and has been shown to play a role in the regulation of immune responses.

The potential of DHRS4-AS1 as a drug target is based on its involvement in various physiological processes and its ability to interact with various signaling pathways. Its expression has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As research continues to advance, DHRS4-AS1 is likely to become a valuable tool for the development of new treatments for a variety of diseases.

Protein Name: DHRS4 Antisense RNA 1

The "DHRS4-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DHRS4-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets